Dato-DXd + Carboplatin + Cisplatin + Gemcitabine
Phase 2/3Recruiting 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urothelial Cancer
Conditions
Urothelial Cancer, Bladder Cancer
Trial Timeline
Sep 26, 2025 → Jan 22, 2030
NCT ID
NCT07129993About Dato-DXd + Carboplatin + Cisplatin + Gemcitabine
Dato-DXd + Carboplatin + Cisplatin + Gemcitabine is a phase 2/3 stage product being developed by Daiichi Sankyo for Urothelial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07129993. Target conditions include Urothelial Cancer, Bladder Cancer.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07129993 | Phase 2/3 | Recruiting |
Competing Products
20 competing products in Urothelial Cancer